Financials data is unavailable for this security.
View more
Year on year Jilin Province Huinan Changlong Bio-pharmacy Co Ltd 's net income fell -23.43% from 193.57m to 148.21m despite relatively flat revenues. A contributing factor has been an increase in the percentage of sales devoted to the cost of goods sold from 23.00% to 30.60%.
Gross margin | 75.46% |
---|---|
Net profit margin | 20.46% |
Operating margin | 26.16% |
Return on assets | 7.31% |
---|---|
Return on equity | 10.76% |
Return on investment | 10.25% |
More ▼
Cash flow in CNYView more
In 2023, Jilin Province Huinan Changlong Bio-pharmacy Co Ltd increased its cash reserves by 209.98%, or 238.54m. The company earned 315.95m from its operations for a Cash Flow Margin of 37.54%. In addition the company generated 109.04m cash from investing, though they paid out 186.45m more in financing than they received.
Cash flow per share | 0.2263 |
---|---|
Price/Cash flow per share | 5.75 |
Book value per share | 3.11 |
---|---|
Tangible book value per share | 3.10 |
More ▼
Balance sheet in CNYView more
Current ratio | 1.74 |
---|---|
Quick ratio | 1.62 |
Total debt/total equity | 0.0529 |
---|---|
Total debt/total capital | 0.0502 |
More ▼
Growth rates in CNY
Year on year, growth in earnings per share excluding extraordinary items dropped -23.43%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years) | -1.67 |
---|---|
EPS (TTM) vs TTM 1 year ago | -- |